help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hallengren, B.
Right arrow Articles by Melander, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hallengren, B.
Right arrow Articles by Melander, A.

Journal of Clinical Endocrinology & Metabolism, Vol 51, 298-301, Copyright © 1980 by Endocrine Society

ARTICLES

Effects of antithyroid drugs on lymphocyte function in vitro

B Hallengren, A Forsgren and A Melander

The in vitro influence of 6-propylthiouracil (PTU) and methimazole (MMi) on mitogenic activation of human peripheral blood lymphocytes was studied in order to assess whether antithyroid drugs may have an immunomodulatory capacity. Lymphocytes were cultured for 72 h in the presence of phytohaemagglutinin (PHA; 1.25 microgram/ml), concanavalin A (Con A; 5.0 microgram/ml), or pokeweed mitogen (PWM; 2.5 microgram/ml). Antithyroid drugs were added to yield final concentrations of 1-1000 mu mol/liter. High pressure liquid chromatographic analyses verified that the expected drug concentrations in the incubation media were reached and maintained throughout the incubation period. The degree of lymphocyte activation was assessed by measurements of the cellular uptake of [3H]thymidine added after 48 h. PTU (at 1000 mu mol/liter) slightly suppressed PHA- and Con A-induced activation of lymphocytes but enhanced (at 5-500 mu mol/liter) PWM- induced activation. MMI (500-1000 mu mol/liter) enhanced not only PWM- induced activation but (at 1000 mu mol/liter) also enhanced PHA- and Con A-induced activation. Thus, PTU and MMI might interfere with mitogenic activation of lymphocytes. However, the effects were mainly recorded at drug concentrations exceeding those found in blood samples of patients treated with conventional doses.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
A. J Klecha, A. M Genaro, G. Gorelik, M. L. Barreiro Arcos, D. M. Silberman, M. Schuman, S. I Garcia, C. Pirola, and G. A Cremaschi
Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway.
J. Endocrinol., April 1, 2006; 189(1): 45 - 55.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. Montani, M. Shong, S.-i. Taniguchi, K. Suzuki, C. Giuliani, G. Napolitano, J. Saito, M. Saji, B. Fiorentino, A. M. Reimold, et al.
Regulation of Major Histocompatibility Class II Gene Expression in FRTL-5 Thyrocytes: Opposite Effects of Interferon and Methimazole
Endocrinology, January 1, 1998; 139(1): 290 - 302.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society